Diabetes Breakthroughs Offer Hope—but Millions Still Lack Access to Diagnosis and Care

November 19, 2026
Diabetes Breakthroughs Offer Hope—but Millions Still Lack Access to Diagnosis and Care
  • Diabetes treatments are advancing, but their promise will reach only a fraction of those who need them unless people can access diagnosis and care; more than 830 million people were estimated to have diabetes in 2026, and a 2023 model projected that figure could exceed 1.3 billion by 2050.

  • For Type 1 diabetes, blood tests can detect early immune signs before symptoms or rising blood sugar, creating an opportunity for earlier treatment; screening is available in the U.S. for people with an affected family member, while European experts have called for broader screening because most people diagnosed have no affected relative.

  • For people whose immune systems have begun attacking insulin-producing cells, teplizumab can delay Type 1 diabetes progression by up to three years, giving patients and families time to prepare.

  • Cell-transplant trials for Type 1 diabetes have helped most participants stop insulin or substantially reduce their doses, lowering the risk of dangerously low blood sugar; immune rejection and the risks of long-term immunosuppressant use remain major obstacles, and researchers are testing ways to protect transplanted cells or selectively prevent immune attacks.

  • GLP-1 medicines can do more than lower blood sugar: studies associate them with fewer deaths, hospitalizations and amputations among high-risk people with Type 2 diabetes, and suggest they may help prevent the disease in people with elevated blood sugar.

  • Lifestyle interventions have also shown promise for early-onset Type 2 diabetes: an October 2026 trial found that more than half of participants were in remission six months after starting a low-calorie diet and supervised exercise, while a 2025 study reported sustained remission for up to three years among more than half of participants using an AI-guided lifestyle app.

  • Yet access remains a major barrier: more than 250 million people worldwide with Type 2 diabetes may not know they have it, only about half can access needed insulin, and GLP-1 medicines and Type 1 screening remain scarce or unaffordable in many lower-income settings.

  • The gaps are reflected in a T1International survey of more than 1,000 people, in which over a third said they had rationed diabetes supplies in the previous year because of cost; screening and early Type 1 treatment are also rarely available in low- and middle-income countries, and the COVID-19 pandemic made care harder to access.

  • Making insulin easier to manufacture and distribute, alongside a stronger focus on affordable care, could help extend the benefits of both new and existing treatments; the article invokes insulin co-discoverer Frederick Banting’s vision that insulin should be for the world.

Summary based on 2 sources


Get a daily email with more Science stories

More Stories